Tony Tipton appointed as Crossject’s US Operations Director to commercialize ZEPIZURE®, an emergency treatment for epileptic seizures – 08/19/2024 at 6:48 p.m.

Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing emergency medicines delivered with its award-winning ZENEO® needle-free auto-injector, announces the appointment of veteran healthcare executive Tony Tipton as Chief Operating Officer, U.S.

With over 25 years of experience in key sectors of the commercial pharmaceutical industry, he brings expertise in corporate governance and development, market access, commercial leadership, marketing and commercial operations. He joins Crossject from Xequel Bio, where he was responsible for commercialization strategy and pre-commercial activities for BARDA and NIH-funded assets as well as acquired commercial assets. Mr. Tipton’s appointment will strengthen Crossject’s pre-commercial activities in the United States during the preparation of the ZEPIZURE® marketing authorization application.